Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment

Background: Patients with ulcerative colitis (UC) frequently require long-term therapy to prevent relapse. Treatments such as 5-aminosalicylic acid (5-ASA [mesalazine]) are efficacious and well tolerated, but adherence to treatment is often poor.